Priscilla Jebaraj

NEW DELHI: The Biotechnology Regulatory Authority of India (BRAI) will only deal with the safety and efficacy aspects of biotech products, leaving the controversial commercialisation aspect hanging in the air, according to the latest version of the BRAI Bill, 2010.

The Bill, which was supposed to be introduced in the last session of Parliament, is back in limbo after object